Advice for Oncologists and Next Steps for the CLEAR Trial in RCC
Viktor Grünwald, MD, PhD, discusses what findings from the post hoc analysis of the CLEAR trial of lenvatinib plus pembrolizumab vs sunitinib for patients with renal cell carcinoma mean for community oncologists.
Efficacy of Lenvatinib Plus Pembrolizumab and Sunitinib in Advanced RCC
Viktor Grünwald, MD, PhD, reviews the efficacy findings of lenvatinib combined with pembrolizumab and sunitinib for the treatment of patients with advanced renal cell carcinoma.